Discover
XFOR
X4 Pharmaceuticals, Inc.
2.91
4 x 2.91
2 x 3.63
bid
ask
+
0.12
4.30%
3 @ 04:47 PM
2.91 +0.00 (0.00%)
| Ytd | -27.25% | |
| 1y | -15.16% |
2.81
day range
2.96
2.77
52 week range
4.67
| Open | 2.83 | Prev Close | 2.79 | Low | 2.81 | High | 2.96 | Mkt Cap | 288.52M |
| Vol | 541.23K | Avg Vol | 849.58K | EPS | 0.02 | P/E | 145.50 | Forward P/E | -1.23 |
| Beta | 0.39 | Short Ratio | 8.64 | Inst. Own | 67.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.72 | 200-d Avg | 3.89 | 1yr Est | 3.05 |
| Income Statement | |||
| Total Revenue | 8.81M | ||
| Revenues (USD) | 8.81M | ||
| Cost of Revenue | 1.62M | ||
| Gross Profit | 7.19M | ||
| Operating Expenses | 23.58M | ||
| Research and Development Expense | 15.08M | ||
| Selling, General and Administrative Expense | 8.50M | ||
| Operating Income | -16.39M | ||
| Interest Expense | 2.16M | ||
| Income Tax Expense | 2.00K | ||
| Net Income | -16.16M | ||
| Net Income Common Stock | -16.16M | ||
| Net Income Common Stock (USD) | -16.16M | ||
| Consolidated Income | -16.16M | ||
| Earnings per Basic Share | -0.13 | ||
| Earnings per Basic Share (USD) | -0.13 | ||
| Earnings per Diluted Share | -0.13 | ||
| Earning Before Interest & Taxes (EBIT) | -13.99M | ||
| Earning Before Interest & Taxes (USD) | -13.99M | ||
| Weighted Average Shares | 126.34M | ||
| Weighted Average Shares Diluted | 126.34M | ||
| Balance Sheet | |||
| Cash and Equivalents | 195.10M | ||
| Cash and Equivalents (USD) | 195.10M | ||
| Investments | 12.87M | ||
| Investments Current | 12.87M | ||
| Trade and Non-Trade Receivables | 2.05M | ||
| Current Assets | 218.86M | ||
| Property, Plant & Equipment Net | 765.00K | ||
| Total Assets | 253.06M | ||
| Debt Current | 465.00K | ||
| Total Debt | 77.22M | ||
| Current Liabilities | 19.37M | ||
| Debt Non-Current | 76.76M | ||
| Total Liabilities | 97.61M | ||
| Accumulated Retained Earnings (Deficit) | -630.95M | ||
| Accumulated Other Comprehensive Income | -123.00K | ||
| Shareholders Equity | 155.45M | ||
| Shareholders Equity (USD) | 155.45M | ||
| Assets Non-Current | 34.21M | ||
| Total Debt (USD) | 77.22M | ||
| Deferred Revenue | 1.43M | ||
| Goodwill and Intangible Assets | 30.45M | ||
| Inventory | 5.50M | ||
| Liabilities Non-Current | 78.24M | ||
| Trade and Non-Trade Payables | 3.93M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.38M | ||
| Net Cash Flow from Financing | 75.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -21.72M | ||
| Capital Expenditure | -5.00M | ||
| Issuance (Purchase) of Equity Shares | 77.00K | ||
| Net Cash Flow from Investing | -1000.00K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 4.00M | ||
| Net Cash Flow from Operations | -20.79M | ||
| Effect of Exchange Rate Changes on Cash | -5.00K | ||
| Share Based Compensation | 3.09M | ||